French pharmaceutical company Sanofi and the US-based MannKind Corporation have entered into an exclusive licensing agreement to develop and commercialise MannKind’s Afrezza (insulin human), an inhalable insulin therapy for adults with types 1 and 2 diabetes.
New Jersey-based pharmaceutical company Merck has sued generic drug maker Fresenius for infringing patents relating to its anti-fungal injection Cancidas (caspofungin acetate).
The US Food and Drug Administration (FDA) has issued guidance for biological drug makers about what information they should provide the agency to determine when their products’ marketing exclusivity period should begin, known as the “date of first licensure”.
The US Court of Appeals for the Federal Circuit has affirmed a district court’s decision that pharmaceutical company Tyco’s patents directed to sleep aid drug temazepam were not infringed.
US District Court for the Northern District of California judge Lucy Koh has dismissed Japanese pharmaceutical company Takeda’s patent infringement case against generic maker Mylan concerning acid reflux drug Dexilant (dexlansoprazole).
US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive.
New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4.
Anglo-Swedish pharmaceutical company AstraZeneca has sued India-based Zydus for infringing three patents related to its heartburn drug Nexium (esomeprazole magnesium).
German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug.
Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.